BioLineRx (NASDAQ: BLRX) announced that following promising pre-clinical data, EDP-14, for the treatment of severe and persistent asthma, has been ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE